Increased reporting of venous and arterial thromboembolic events reported with tixagevimab–cilgavimab for coronavirus disease 2019

OBJECTIVES: As two phase three clinical trials indicated a disproportion in the number of thromboembolic events in the tixagevimab/cilgavimab group than in the placebo group, there has been a cardiovascular safety concern with the use of anti–SARS-CoV-2 monoclonal antibody (mAb). Whether tixagevimab...

Descripción completa

Detalles Bibliográficos
Autores principales: Montastruc, François, Lafaurie, Margaux, Flumian, Clara, de Canecaude, Claire
Formato: Online Artículo Texto
Lenguaje:English
Publicado: European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd. 2023
Materias:
Research Note
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9714079/
https://www.ncbi.nlm.nih.gov/pubmed/36464214
http://dx.doi.org/10.1016/j.cmi.2022.11.026

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9714079/
https://www.ncbi.nlm.nih.gov/pubmed/36464214
http://dx.doi.org/10.1016/j.cmi.2022.11.026

Ejemplares similares